News

November 16, 2011 – Johnson & Johnson Pharmaceutical Research & Development announced that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite...

November 15, 2011 — A clinical trial of patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and stable angina showed rapid genotyping followed by...

November 15, 2011 — A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was...

November 15, 2011 — Results of ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT)...

November 15, 2011 — Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who...

November 11, 2011 — The 30-day results from the 8,500+ patient ADAPT-DES registry were presented at the 2011 TCT conference in San Francisco. Patients with high platelet reactivity, as measured by...

November 9, 2011 – AstraZeneca announced that a combined expert committee of American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and Society for Cardiovascular...

November 9, 2011 — Janssen Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has approved Xarelto to reduce the risk of stroke and systemic embolism in patients with...

October 24, 2011 – The American College of Cardiology (ACC) announced it is expanding its outpatient PINNACLE Registry with a new platform focusing on atrial fibrillation (AF), including the next...

September 15, 2011 – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular...

September 8, 2011 – A randomized multicenter, open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months'...

September 6, 2011 — The European Society of Cardiology (ESC) released the latest version of its guidelines for managing patients presenting without persistent ST-segment elevation. This version...

August 18, 2011 — The antiplatelet agent prasugrel (trade name Effient), in combination with aspirin, was associated with 26 percent relative risk reduction in cardiovascular death, myocardial...

July 21, 2011 – The U.S. Food and Drug Administration (FDA) today approved AstraZeneca’s blood-thinning drug ticagrelor (Brilinta) to reduce cardiovascular death and heart attack in patients with...

April 7, 2011 – Primary results from the RADAR Phase 2b clinical trial were announced at the American College of Cardiology (ACC) 2011 60th Annual Scientific Session. The trial looked at Regado...

April 7, 2011 – New study results have evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on clopidogrel (Plavix). The results showed that in healthy subjects,...

April 1, 2011 – Oral antiplatelet therapy Effient (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing...

April 1, 2011 –Results from the RADAR Phase 2b clinical trial will be announced at the i2 Summit during the American College of Cardiology (ACC) 2011 Annual Scientific Session and Expo. The trial...

March 25, 2011 – The American College of Cardiology (ACC) and the American Heart Association (AHA) have released a focused update to the 2007 guidelines for the managing patients with unstable...

March 10, 2011 – New guidelines have been published in The Annals of Thoracic Surgery that include point-of-care testing for platelet reactivity as a new recommendation for...